Pharmacogenomics and clinical significance of rhabdomyosarcoma in children / 国际肿瘤学杂志

ABSTRACT

Rhabdomyosarcoma is a common soft tissue malignant tumor in children.Multi-disciplinary combination therapy based on chemotherapy can improve the survival rate.Studies in chemotherapeutic pharmacogenomics indicate that the main cause of differences in individual drug responses is genetic polymorphism.Chemotherapy regimen include vincristine,actinomycin D,cyclophosphamide,irinotecan etc.CYP3A5 gene is related to neurotoxicity of vincristine,and ABCB1 gene is related to clearance rate of actinomycin D.CYP2C9 high expression makes increased hemorrhagic cystitis risk with cyclophosphamide.CYP2B6 is a predictor of neutrophil reduction in doxorubicin.UGT1A1 gene polymorphism is associated with severe diarrhea and neutropenia of irinotecan and CYP3A4 affects metabolism of etoposide.Detection of chemotherapeutic drug gene expression before treatment and adjustment of chemotherapy regimens can reduce adverse reactions and provide the possibility of individualized precision treatment.